Missoula, Montana-based Inimmune Corporation has announced the initiation of Phase 1/1b trial of its INI-2004 intranasal toll-like receptor 4 agonist, which the company is developing for the treatment of allergic rhinitis. According to the company, the Phase 1 SAD portion of the study, which is taking place in Australia, will enroll healthy volunteers and patients with allergic rhinitis. The Phase 1b MAD portion of the trial will take place in the US in allergic rhinitis patients, the company said, noting that the FDA has already cleared the IND.
Inimmune Chief Medical Officer Jon Ruckle commented, “Australia is the ideal location for us to conduct a cost-effective, high-quality Phase 1 study. We already have in place an Australian subsidiary, an experienced Phase 1 clinical site, and a relationship with a well-respected local contract research organization.”
CEO Alan Joslyn said, “We are thrilled to have accomplished these momentous milestones. These are important milestones for our company, representing our first program to receive FDA clearance to enter the clinic and our first dosing in a FIH clinical trial, demonstrating our drug discovery and clinical development capabilities. INI-2004 leverages our groundbreaking science as it was designed to be allergen-agnostic and can potentially be an effective treatment for multiple allergic diseases.”
Read the Inimmune press release.
